Alluvi Healthcare Tirzepatide 40mg

Rated 4.00 out of 5 based on 1 customer rating

‍A 40mg Tirzepatide formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications. Delivered in sealed format to support compound stability analysis, formulation studies, and delivery mechanism evaluation.

Each Tirzepatide 40mg Research kit includes:
Pre-filled Research pen (40mg Tirzepatide)
Research information sheet

‍Storage:
Store refrigerated (2–8°C). Do not freeze.
Supplied in fixed-volume sealed format for laboratory analysis.

‍Delivery: Dispatched with a cold pack.
Tracked 2 DAY US Delivery.

$169.00

Category: ALLUVI HEALTHCARE Tag: Alluvi Healthcare Tirzepatide 40mg

Description
Reviews (1)

Alluvi Healthcare Tirzepatide 40mg

Alluvi healthcare Tirzepatide 40mg is a prescription peptide that acts as a dual GIP and GLP-1 receptor agonist. It’s FDA-approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Alluvi Healthcare Tirzepatide 40mg typically refers to a vial containing 40mg total of tirzepatide, which a provider may use for multi-dose regimens or titration under medical supervision.

How It Works

Tirzepatide mimics two gut hormones that regulate blood sugar and appetite. It increases insulin release when glucose is high, lowers glucagon secretion, slows gastric emptying, and reduces hunger signals in the brain. The result is improved A1c and clinically significant weight loss in trials. It’s administered once weekly by subcutaneous injection.

Approved Dosing vs 40mg Vials

The FDA-approved maintenance doses for tirzepatide are 2.5mg to 15mg once weekly. A 40mg vial is not a single-dose strength; it’s a total quantity intended to be divided into multiple doses by a licensed prescriber or pharmacy. Off-label or compounded use should only occur with medical oversight.

Important Considerations

– Prescription Required: Tirzepatide is not OTC. You need a clinician to evaluate risks and monitor treatment.

– Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite are most frequent, especially during dose increases.

– Boxed Warning: Rodent studies showed thyroid C-cell tumors. It’s contraindicated with a personal/family history of medullary thyroid carcinoma or MEN 2.

– Quality & Safety: Only obtain from licensed pharmacies. Compounded peptides must have third-party testing for sterility, potency, and purity.